期刊
EMBO MOLECULAR MEDICINE
卷 13, 期 4, 页码 -出版社
WILEY
DOI: 10.15252/emmm.202013076
关键词
glia; neuroinflammation; Parkinson’ s disease; serum; glucocorticoid related kinase 1; synuclein alpha
资金
- National Research Foundation of Korea (NRF) of the Ministry of Science and ICT, Republic of Korea [2017R1A5A2015395, 2017M3A9B4062415, 2020M3A9D8039925]
- University of Seoul
- National Research Foundation of Korea [2017R1A5A2015395, 2017M3A9B4062415, 2020M3A9D8039925] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Inhibiting SGK1 in glial cells corrects their pro-inflammatory properties, enhances their ability to scavenge glutamate toxicity, and prevents glial cell senescence and mitochondrial damage, showing potential therapeutic value for treating neurodegenerative disorders like PD and AD.
Astrocytes and microglia are brain-resident glia that can establish harmful inflammatory environments in disease contexts and thereby contribute to the progression of neuronal loss in neurodegenerative disorders. Correcting the diseased properties of glia is therefore an appealing strategy for treating brain diseases. Previous studies have shown that serum/ glucocorticoid related kinase 1 (SGK1) is upregulated in the brains of patients with various neurodegenerative disorders, suggesting its involvement in the pathogenesis of those diseases. In this study, we show that inhibiting glial SGK1 corrects the pro-inflammatory properties of glia by suppressing the intracellular NF kappa B-, NLRP3-inflammasome-, and CGAS-STING-mediated inflammatory pathways. Furthermore, SGK1 inhibition potentiated glial activity to scavenge glutamate toxicity and prevented glial cell senescence and mitochondrial damage, which have recently been reported as critical pathologic features of and therapeutic targets in Parkinson disease (PD) and Alzheimer disease (AD). Along with those anti-inflammatory/neurotrophic functions, silencing and pharmacological inhibition of SGK1 protected midbrain dopamine neurons from degeneration and cured pathologic synuclein alpha (SNCA) aggregation and PD-associated behavioral deficits in multiple in vitro and in vivo PD models. Collectively, these findings suggest that SGK1 inhibition could be a useful strategy for treating PD and other neurodegenerative disorders that share the common pathology of glia-mediated neuroinflammation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据